Hjem › Diffust stort B-celle lymfom › Tennessee › Nashville
Diffust stort B-celle lymfom kliniske forsøg i Nashville, TN
15 studier for Diffust stort B-celle lymfom søger deltagere på steder i og omkring Nashville (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RekruttererFase 2
- Vanderbilt University Medical Center, Nashville
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
RekruttererFase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekruttererFase 1/2
- Tennessee Oncology, Pllc Nashville, Nashville
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
RekruttererFase 1/2
- SCRI Oncology Partners ( Site 0100), Nashville
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RekruttererFase 2
- SCRI Oncology Partners ( Site 7002), Nashville
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RekruttererFase 1
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekruttererFase 1
- SCRI Oncology Partners, Nashville
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RekruttererFase 1
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
RekruttererFase 2
- Tennessee Oncology, Nashville
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
RekruttererFase 1/2
- Sarah Cannon Research Institute, Nashville
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RekruttererFase 1/2
- Vanderbilt University Medical Center, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekruttererFase 1/2
- TriStar BMT, Nashville
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RekruttererFase 3
- SCRI Oncology Partners, Nashville
DALY II USA/ MB-CART2019.1 for DLBCL
RekruttererFase 2
- SCRI Oncology Partners, Nashville
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RekruttererFase 1
- Tennessee Oncology, Nashville
Diffust stort B-celle lymfom forsøg i andre byer
- New York City, NY21 studier
- Baldwin Park, CA19 studier
- Chicago, IL18 studier
- Houston, TX17 studier
- Los Angeles, CA17 studier
- Boston, MA16 studier
- Milwaukee, WI16 studier
- Portland, OR15 studier
- Philadelphia, PA15 studier
- Durham, NC14 studier
- Dallas, TX13 studier
- Seattle, WA12 studier
Andre studier i Nashville
- Ikke-småcellet lungecancer97 studier
- Brystkræft80 studier
- Metastatisk cancer70 studier
- Colorektal kræft69 studier
- Kræft (alle typer)65 studier
- Ægstockræft49 studier
- Prostatakræft42 studier
- Lungecancer40 studier
- Pladecellekræft i hoved og hals39 studier
- Bugspytkirtelkræft39 studier
- Livmoderslimhindekræft38 studier
- Melanom33 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.